Brad joined Varro from Cellja Vu, Inc, where he served as CEO. Mr. Theien was previously the VP of Corporate and Commercial Development at Filament Biosolutions, and he worked in the Strategy, Portfolio and Commercial Operations group at Pfizer. Mr. Theien also was a biopharmaceutical equity analyst at Prudential Securities where he covered several small-cap biotechnology companies. Mr. Theien received a MS in Biotechnology and an MBA from Northwestern University.
